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A solid s upport radioimmunoassay has been developed 
to detect immunoglobulin specific circulating antibodies 
to polyuridylic acid (Poly U), single-stranded RNA (ss 
RNA), and single-stranded DNA (ss DNA) in scleroderma 
and othe r connective tissue diseases. The assay system 
uses flex-vinyl microtiter plates on which bovine methyl 
albumin, the respective polynucleotide, a 1:80 dilution of 
patient serum, and tritiated high affinity anti-IgG, -IgA, 
or -IgM are layered. The individual wells containing the 
sandwich assay are then counted for the presence of 
labeled immunoglobulins and the results are reported in 
llg/ml. 
Of the 30 scleroderma patients tested, only patients 
with diffuse systemic scleroderma had antibody levels 
reactive to Poly U >4.0 ~tg/ml and toss RNA< 3.0 llg/ml. 
Patients with linear scleroderma or morphea had anti-
body levels to Poly U <3.0 ,...g;ml and very little antibody 
to ss DNA or ss RNA in their sera. Partial cross reactivity 
to Poly U was found only in SLE patients with high levels 
of Ab to ss DNA. Insignificant levels of Poly U antibody 
were found in patients with other cormective tissue dis-
eases and in normal controls. 
High levels of serum antibody in patients which re-
acted with Poly U suggest active diffuse systemic scle-
roderma. 
T he etiology of scleroderma has been investigated from a 
variety of approaches including detection of abnormalities of 
the microvascular system [l-4] biochemical abnormalities of 
the collagen [5-8) and morphological changes.[9- ll). Recently, 
a number of immunological abnormalities have been reported, 
such as the association of systemic scleroderma with autoim-
mune hemolytic anemia, graft NS. host disease, and the high 
incidence of antinuclear antibodies [12- 15). Antibodies to var-
ious types of RNA or RNA-protein have also been found in 
patients with scleroderma, systemic lupus erythematosus 
(SLE) , Sjogren's syndrome, mixed connective tissue disease, 
and Raynaud's phenomenon [16). 
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Abbreviations: 
ANA: antinuclear antibody 
AS: acrosclerosis 
BAC: bromoacetyl cellulose 
DS: diffuse scleroderma 
FDNB: 3H flu orodini trobenzene 
MBSA: methylated bovine serum albumin 
RAST: radioallergosorbent 
SLE: systemic lupus erythematosus 
SPRIA: so lid phase radioimmunoassay 
Alarcon-Segovia and Fishbein (17] have shown that many 
scleroderma patients have antibodies that react with macil-
specific ssRNA as detected by counter-immunoelectrophoresis. 
Because uracil-specific ssRNA might be an immunological 
marker of the disease or involved in the disease process, we 
decided to investigate the incidence of antibodies to polyuridylic 
acid in the various connective tissue diseases. Using a solid 
state radioimmunoassay technique, we have detected a popu-
lation of auto-antibodies which binds to the synthetic poly-
nucleotide, polyuridylic acid (Poly U), in the sera of most 
patients with diffuse scleroderma (DS) . 
MATERIALS AND METHODS 
Clinical Material 
Patients having scleroderma were classified either as localized skin 
disease which included morphea and linear scleroderma, or systemic 
scleroderma. The patients having systemic scleroderma were further 
subdivided into (1) diffuse scleroderma (with skin involvement of more 
than face and distal extremities) or (2) acrosclerosis (AS) wi th Ray-
naud's phenomenon and skin involvement restricted to the face and/or 
distal extremities. The disease of these patients was classified as active 
when new organ systems became involved, skin induration (hide bind-
ing) increased, and/or involved surface aJ"ea increased. 
Patients were classified as having Raynaud's disease only when there 
were ab_solu~ely no clinical signs or symptoms of possible underlying 
connect1ve tissue disease. Pa tients were classified as having acroscle-
rosis if there was no more cutaneous involvement than the distal 
extremities and/or the face. Patients with other connective t issue 
diseases were included in this paper only if their diagnosis had been 
weU established by appropriate clinical and laboratory criteria. The 
actual numbers of patients with the various connective tissue disease 
tested are contained in the results section. 
Venous blood was drawn from patients with various connective tissue 
diseases and from normal controls. The samples of patients' sera, taken 
at various times during the course of the disease, were received within 
6 hr after drawing, and the sera was separa ted by centrifugation at 4 °C. 
Samples were stored at -5° to -10°C and thawed once before testing. 
Sera were selected for testing when the patient's disease appeared to 
be most immunologically active. 
Radioallergosorbent (RAST) Buffer lOX Solution 
Thirty grams of Dextran T 70 (Pharmacia) were dissolved in 500 ml 
of 0.9% saline. The remaining reagents were then dissolved in their 
respective order: 85 gm Nal'I.PO, . H20; 85.5 gm NaCl; 3.0 gm NaN3; 
50 ml Tween 20; volume was brought up to 1000 ml with distilled H20 
and to a pH of 7.2. The working solution used was a 1:10 dilution 
(distilled H20) of the above with a pH of 7.2. 
S ingle-stranded Polyuridylic Acid (Poly U, RNA and DNA) 
Single-stranded Poly U was made from double-stranded Poly U 
(Sigma) by dissolving (1 mg/ml) in distilled water and bringing up to 
volume (1 mg/10 ml) with RAST buffer pH 7.2. The solu tion was 
heated atl00°C for 12 min, then quickly cooled in ice water. This same 
method was used to obtain the single-stranded forms of RNA (Type II 
Sigma) and DNA (Type I Sigma). Partia l reannealment of less than 5% 
may occur in these nucleic acids [18). 
High Affinity Anti-lgG 
Pooled normal serum was fractionated wi th a 15% final volume 
NazSO, solution to precipitate the immunoglobu lins, which were then 
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dissolved to origina l volume with distilled H20 and chromatographed 
on a G-200 Sephadex column to obtain the lgG fraction. The lgG 
fraction was bound to bromoacetyl cellulose (BAC) (approx. 45.0 mg 
IgG/gram of BAC) according to the method of Robbins (19]. After 
appropriate washing, goat anti-human lgG (Fe specific-Cappel) was 
incubated with the matrix (9.0 mg Ab/gm matrix) for 4 hr at 25°C with 
gentle shaking. After washing twice with 0.9% saline, the matrix was 
treated with pH 4.5 0.01 M acetate-buffered saline for 10 min, washed 
once with 0.9% saline, and was then treated with 0.017 M HCl-buffered 
saline pH 2.5 to remove high affinity anti-lgG. The eluted high affinity 
anti-IgG was then neutralized by adding 0.15 M NaHCO:~ and the 
concentration was determined by a modified Lowry protein determi-
nation [20] and double-immunodiffusion (21]. 
Both high affinity anti-lgM and -IgA were isolated by similar meth-
ods as that for high affinity anti-lgG, using goat anti- human lgM or 
IgA heavy chain specific anti-sera (Cappel). Human IgM was obtained 
by G-200 chromatography of at least 6 pooled patient sera samples 
after NazSO. precipitation. The lgA used as the antigen on immunoab-
sorbent matrix was obtained from a pool of the sera of 6 lgA myeloma 
patients. 
3H Labeling of High A ffinity An.ti-IgG 
The general method of Sanger [22) was used to label high affinity 
anti-IgG with 3H Fluorodinitrobenzene (FDNB). A solution of 500 1-Lg 
anti-IgG/1.0 ml saline (0.9%) was raised to a pH of 9.0 by the addition 
of 2 ml of 0.15 M sodium borate-buffered saline. This solu tion is 
immediately added to benzene-evaporated FDNB and allowed to react 
for 2 h1· on a rocker platform. Generally, 10 molecules of FDNB will 
label! molecule of anti-IgG suffic iently. Excess 3H FDNB was removed 
by desalting with a PD-10 column (Pharmacia) and PBS pH 7.2 and 
total CPM were calculated per ng of anti-IgG. 
Quantitation of Worllin.g Curve for RIA 
Quantitation of working curves of patients' anti-Poly U antibodies 
and 3H labeled anti-immunoglobulins were obtained by making dilu-
tions of both components in a grid manner. To find the best working 
dilution of the serum we used series of 2-fold dilutions from anti-Poly 
U positive (determined by double-diffusion and counter-immunoelec-
trophoresis) patients' sera ranging from 1:20 to 1:640 with a series of 
labeled anti-IgG concentrations ranging from 20 ng to 200 ng/well. 
Each series was plotted and the best working curve was selected. A 1: 
80 dilution of patients' sera provided a concentration of anti-Poly U 
antibodies that would not saturate all the antigenic sites of the Poly U. 
Similar t itration curves were used to determine the lgM and lgA anti-
Poly U antibody concentration in patients' sera. 
Solid Phase Radioimmunoassay (RIA) 
The solid phase microtiter radioimmunoassay of Tan and Epstein 
[23] was modified by incorporating the HAST technique for immuno-
globulin specificity. Flexible, polyvinyl, 96-well micro titer U plates were 
etched 5 min per well with spectra l-grade toluene, washed 3 times with 
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FIG 1. The sandwich assay system of the radiOimmunoassay. 
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FIG 2. Compa1·isons of concentrations of IgG antibodies to Poly U 
in the various connective tissue diseases. DS=diffuse scleroderma; 
AS=acrosclerosis; R=Raynaud 's disease; M=morphea; LS=linear 
scleroderma; DM =dermatomyositis; BP =bu llous pemphigoid; 
SLE=systemic lu pus erythematosus (active); N=normal human serum; 
RA=rheumatoid arthritis. The antibody levels to Poly U of active 
diffuse scleroderma were significantly higher (p > .001) than levels of 
the other types of scleroderma or of other connective tissue diseases, 
with Raynaud's disease being significantly different (p > .01) from the 
normals. 
PBS pH 7.2, and once with distilled H20. The plate was coated with 0.1 
ml methylated bovine serum albumin (MBSA) per well (1 mg/ 10 ml 
H20) , incubated for 4 hr at room temperature, and wash ed 3 times with 
PBS pH 7.2. S ingle-stranded Poly U, single-stranded RNA, or single-
stranded DNA (10 1-Lg/ 0.1 ml RAST) was applied to the MBSA coated 
wells and incubated at 4°C for 12 hr fo llowed by 6 washings with HAST 
buffer. 
Patients' sera (0.1 ml/well) of a 1:80 dilution in RAST buffer were 
added to the respective wells in duplicate and incubated at room 
temperature for 4 hr fo llowed by 6 washings with RAST buffer. High 
affinity labeled anti-IgG, -IgM or -IgA (0.1 ml/ well: 40 ng/ mlunlabeled 
and 40 ng/ ml labeled A b) was added to the respective wells, incubated 
for 12 hours at room temperature and washed 6 times with HAST 
buffer. The wells were cut from the plate and placed in scin tillation 
vials. After liquid scintillation cocktail (any type suitable for counting 
aqueous solutions and organic soluble samples) was added to the vials, 
they were allowed to stand one hour at room temperature before 
counting for the presence of labeled anti-immunoglobulin. The counts 
per minute per ng were determined by counting a known volume of a 
dilution of the labeled anti-IgG, -IgM or -lgA. With the CPM/ ng of 
type-specific anti-immunoglobulin established the serum sample was 
calculated as micrograms of IgG, lgM and/ or lgA toss Poly U, ss DNA 
or ss RNA/ well by a linear regression plot (Fig 1). 
RESULTS 
.Ten 'of the 13 patients with diffuse scleroderma had IgG 
antibody reactive with Poly U greater than 4.0 /-(g/ ml as illus-
tl·ated in Fig 2. Eight of these 10 patients were actively devel-
oping new skin lesions or h ad increased plaque induxation at 
the t ime the serum samples were obtained. The 2 other patients 
of this group were found to have been dermatologically more 
active 2 yeru·s prior to obtaining the sera. Eight of these 10 
patients had Raynaud's phenomenon and sclerodactyly and 5 
of t h e 10 had multisystem involvement of heart, lung and/ or 
kidney. Only 1 of the 3 diffuse scleroderma patients that had 
anti-Poly U antibody levels of less than 4 /-(g/ ml had active 
disease; in fact, .this patient was very active with rapidly d evel-
. oping renal disease. 
No highly significant levels of IgG antibodies reactive with 
Poly U (>4.0 f.tg/ ml) were found in patients in any of the other 
disease studied including the patients with acrosclerosis, lin~ar 
scleroderma, and morphea. Smaller a mounts of lgG reactive 
with Poly U (<4.0 /-(g/ ml and >2.0 /-(g/ ml) were found in some 
patients with SLE, rheumatoid arthritis, acrosclerosis, Ray-
naud's di ease, and 1 patient with linear scleroderma. This 
patient with linear scleroderma subsequently developed a sig-
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niticant anti-Poly U level. We found no detectable serum IgA 
antibodies to Poly U in any of the patients tested. 
Three of 12 patients with diffuse scleroderma showed IgG 
antibody to single-stranded RNA greater than 4.0 ,ug/ml (Fig 
3). Four of 18 patients with SLE also showed IgG antibody to 
single-stranded RNA greater than 4.0 _,ug/rnl. These Ig~ . anti-
bodies could possibly be a result of e1ther cross react1v1ty at 
anti-Poly U antibodies with RNA or the presence of antibodies 
in patient sera to many different nucleic acids. The actual 
specificity of all the individual antibodies was not studied. 
Only patients with active systemic lupus erythematosus with 
renal involvement (13 of 13) showed IgG antibody to single-
stranded DNA greater than 4.0 ,ug/rnl (Fig 4). Sera of patients 
with all other connective tissue diseases showed IgG Ab to 
single-stranded DNA considerably below 4.0 ,ug/ml, indicating 
little cross-reactivity between antibodies to Poly U found in DS 
patients and DNA. 
The patients with diffuse scleroderma had antinuclear anti-
body (ANA) patterns mainly consisting of the particulate pat-
terns but not true speckles [15]. Only 1 patient had a serum 
ANA pattern of nucleolar, and 2 patients were negative. 
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FIG 3. Comparison of lgG antibody concentration toss RNA in the 
various connective tissue cliseases. No real differences between diseases 
were noted with the exception of active diffuse scleroderma (p > .001). 
DS=diffuse scleroderma; AS=acrosclerosis; R=Raynaud's disease; 
M=morphea; LS=linear scleroderma; DM=dermatomyositis; 
BP=bullous pemphigoid; SLE=systemic lupus erythematosus (active); 
N=normal human serum; RA=rheumatoid arthritis. 
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FIG 4. Comparison of IgG antibody concentrations toss DNA in the 
various connective tissue diseases. The antibody concentration to ss 
DNA of the active SLE patients was significantly different (p > .001) 
from that of the other connective tissue diseases. DS=diffuse sclero-
derma; AS=acrosclerosis; R=Raynaud's disease; M=morphea; 
LS=linear scleroderma; DM=dermatomyositis; BP=bullous pemphi-
goid; SLE=systemic lupus erythematosus (active); N=normal human 
serum; RA=rheumatoid arthritis. 
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DISCUSSION 
The use of a solid support system to fix the antigen Poly U 
provides a sandwich assay to detect and quantitate the type ?f 
reactive antibody. Since methylated bovine serum albumm 
enables ss DNA, ss RNA or ss Poly U to be fixed to a solid 
matrix it eliminates the need for precipitating a complex found 
in oth~r assays and prevents the reannealment of single-
stranded nucleic acid to the double-stranded form as has been 
previously establish ed using tritiated nu~leic acids (18]. T_he 
use of 3H anti-IgG, -IgM or -IgA prov ides the assay w1th 
immunoglobulin type specificity. 
Our data illustrate that the majority of patients with active 
diffuse scleroderma have IgG antibodies which bind the syn-
thetic polynucleotide, polyuridylic acid. These antibodies were 
not detected in any significant concentration in other types of 
scleroderma or connective tissue diseases, although small 
amounts were found in SLE and RA, which were possibly due 
to cross reactivity of heterogeneous anti-DNA or anti-RNA 
antibodies. Raynaud's disease patients with somewhat eleva~ed 
levels of anti-Poly U antibody may be progressing to an active 
form of diffuse scleroderma or may merely have anti-RNA 
antibodies. We are continuing to monitor these patients to 
ascertain whether the Raynaud's disease may develop into 
diffuse scleroderma. 
One phenomenon that is hard to explain is the lack of 
presence of IgM antibodies in those patients that would react 
with Poly U. When we evaluated active SLE patients who had 
antibodies to DNA, small amounts of IgM antibodies were 
present with the IgG antibodies. The lack of IgM antibodies to 
Poly U might be due to the fact that high affinity IgG antibodies 
are necessary to react with this antigenic site in the test. Low 
affinity antibodies which are usually IgM may be lost in the 
vigorous washing procedure . 
Alarion-Segovia and Fishbein [17] used counter-immunoelec-
trophoresis to detect the reactivity of various serum antibodies 
in patients with systemic scleroderma and SLE. They found 
that the majority of antibodies to RNA in scleroderma patients 
were reactive to uracil bases and not to other components of 
the RNA structme. All 40 of the scleroderma patients they 
studied gave precipitin lines toss RNA and Poly U. In the solid 
phase assay, we use methylated bovine serum albumin as a 
binding agent between the vinyl well of the microtiter plate and 
ss Poly U. This binding is mainly by ionic charge and involves 
the ribose-phosphate components of Poly U, leaving the uridine 
bases open, thus allowing maximal antibody exposure. By using 
such a binding agent we believe the solid phase assay becomes 
very quantitative and qualitative as to which type of antibody 
reacts with Poly U . 
The origin of the antigen is unclear. Pinnas, Northway and 
Tan [24] have tested the sera of patients with predominantly 
nucleolar ANA and have identified a nucleolar antigen, a low 
molecular weight 4-6s RNA, to which they react. Most of these 
patients had either scleroderma or Sjogren's syndrome. Of the 
patients tested in our study, only one had manifested the 
nucleolar ANA pattern; in fact, the ANA patterns were mostly 
confined to the particulates or ANA negative, but not true 
speckles [25]. We can only speculate that the antigen is a type 
of RNA high in uridine base. A few such low molecular weight 
RNAs localized to the nucleus, rich in uridylic acid but not 
produced by the nucleolus, have beer reported [26]. 
In summa1·y, IgG antibodies reactivq t~ the synthetic polymer 
Poly U were found in high concentrations (>4.0 ,ug/rnl) mainly 
in diffuse scleroderma patients and lower levels were found in 
patients having acrosclerosis, Raynaud's disease, and rheuma-
toid arthritis. Quantitative testing for the presence of antibodies 
to Poly U may aid in the diagnosis of active diffuse systemic 
scleroderma. 
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